Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
32.52
-1.68 (-4.91%)
At close: Nov 6, 2026, 4:00 PM EST
32.68
+0.16 (0.48%)
After-hours: Nov 6, 2026, 7:59 PM EST
Castle Biosciences Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Castle Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $46.9. The average 1-year stock price forecast is 44.22% higher than the current stock price, while the lowest is $35 (+7.63%) and the highest is $60 (+84.50%).
Price Target: $46.9 (+44.22%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Castle Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 10 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $40 | Buy | Reiterates | $40 | +23.00% | Nov 6, 2026 |
| Roth MKM | Roth MKM | Buy Maintains $50 | Buy | Maintains | $50 | +53.75% | Nov 6, 2026 |
| Robert W. Baird | Robert W. Baird | Buy Maintains $38 → $39 | Buy | Maintains | $38 → $39 | +19.93% | Nov 6, 2026 |
| KeyBanc | KeyBanc | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +23.00% | Nov 6, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Initiates $60 | Buy | Initiates | $60 | +84.50% | Oct 29, 2026 |
Financial Forecast
Revenue This Year
374.12M
from 344.23M
Increased by 8.68%
Revenue Next Year
419.29M
from 374.12M
Increased by 12.08%
EPS This Year
-1.25
from -0.83
EPS Next Year
-0.94
from -1.25
EPS and Forward PE are based on non-GAAP adjusted numbers.